Process for the preparation of (3e, 7e)-homofarnesol

US2016200648A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2016200648-A1
Application numberUS-201514804747-A
CountryUS
Kind codeA1
Filing dateJul 21, 2015
Priority dateApr 16, 2012
Publication dateJul 14, 2016
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol).

First claim

Opening claim text (preview).

1 .- 12 . (canceled) 13 . A process for preparing (3E,7E)-homofarnesol of formula Ia which comprises a) reacting a carbonyl compound of the formula II in which R 1 is where the dotted line represents a bond to the carbonyl carbon of formula II, and R 2 is methyl, by means of Wittig olefination to give a cyclopropane of the general formula (III) in which R 1 and R 2 have the meanings given above, b) reacting the cyclopropane of the formula III with ring opening in the presence of a Lewis acid or a Brönstedt acid/protonic acid, and a nucleophile, to give a compound of the formula IV in which R 1 and R 2 have the meanings given above, and X is halogen or O—R′, in which R′ is acyl, Tf-acetyl or SO 2 —R″, in which R″ is alkyl or aryl, wherein the ring opening exhibits E-selectively, with respect to R 1 , with a E:Z ratio of greater than 2:1; and c) converting the compound of the general formula IV to the compound of the general formula I by, when X is OR′, carrying out an ester cleavage, or when X is halogen, converting the halide to an ester and then cleaving this ester. 14 . The process according to claim 13 , wherein a cyclopropylphosphonium salt is used for the Wittig olefination according to stage a). 15 . The process according to claim 14 , wherein the cyclopropylphosphonium salt is a triphenylphosphonium compound of the formula V in which Z − is the anion of a strong acid. 16 . The process according to claim 15 , wherein Z is a halide. 17 . The process according to claim 15 , wherein Z is bromide. 18 . The process according to claim 15 , wherein the compound of the formula V is prepared by reacting a) bromobutyrolactone with triphenylphosphine and then thermally decarboxylating the reaction product, or b) reacting 1,3-dibromopropane with triphenylphosphine and then cyclizing the reaction product. 19 . The process according to claim 13 , wherein, in stage c), the compound of the general formula IV is converted to a compound of the general formula I by, when X is OR′, carrying out an ester cleavage, or when X is halogen, converting the halide to an ester and then cleaving this ester. 20 . The process according to claim 13 , wherein, in stage c), the compound of the general formula IV is converted to a compound of the general formula I by, when X is OR′, carrying out an ester cleavage, or when X is halogen, converting the halide to a formate ester, and then cleaving this ester. 21 . The process according to claim 13 , in which a product comprising a (3E,7E)-homofarnesol of the formula Ia is obtained. 22 . The process according to claim 13 , where, in stage a), E-geranyl acetone of the formula IIa is reacted with cyclopropylphosphonium halogenide, so that the cyclopropane of the formula IIIa is obtained. 23 . A compound of the formula IIIa 24 . A process for preparing enantiomerically pure ambrox or a stereoisomer mixture of ambrox, the process comprising; preparing (3E,7E)-homofarnesol by the process according to claim 13 , and conducting a cyclization reaction of the (3E,7E)-homofarnesol chemically or enzymatically to give enantiomerically pure ambrox or a stereoisomer mixture of ambrox.

Assignees

Inventors

Classifications

  • with a three-membered ring · CPC title

  • by elimination of halogen, e.g. by hydrogenolysis, splitting-off (C07C29/124 takes precedence) · CPC title

  • C07D307/92Primary

    Naphthofurans; Hydrogenated naphthofurans · CPC title

  • C07C29/38Primary

    by reaction with aldehydes or ketones · CPC title

  • of halides · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2016200648A1 cover?
The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol).
Who is the assignee on this patent?
Basf Se
What technology area does this patent fall under?
Primary CPC classification C07D307/92. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Thu Jul 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).